secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088054
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL
--------------------------------------------------------------------------------

- Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.
- Grant based on preliminary clinical data (Sept 2023) and non-clinical data (May 2023) showing anti-tumor activity of MT-601.
- Company has now received over $19 million in total non-dilutive funding proceeds.
- APOLLO study evaluates multiTAA-specific T cell product; initial patients showed objective responses with no CRS or ICANS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/0001104659-24-088054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/tm2421372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer